Wound care firm gets $25m series B and new CEO:
This article was originally published in Clinica
PolyRemedy, an Irvine, California company developing a system that can fabricate wound dressings at point of care, has clinched $25m in new capital. Co-leading the series B round were Advanced Technology Ventures (ATV) and IDG Ventures. Other investors that took part in the financing included Harris & Harris Group and existing PolyRemedy shareholder Medventure Associates. In conjunction with the investment, Tom Rodgers from ATV and Michael Greeley from IDG Ventures join the company as board directors. PolyRemedy's robotic system is designed to produce customised, pre-assembled wound dressings at the point of care. The dressings, based on a nano-material, are intended for use on chronic wounds such as diabetic ulcers.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.